Melbourne (Australia) 15 October 2018. Telix Pharmaceuticals Limited announced that it has completed an interim analysis of the ZIR-DOSE dosimetry bridging study, conducted as part of Phase III readiness for 89Zr-TLX250-CDx imaging in metastatic renal (kidney) cancer. The full media release can be accessed here.